AnaptysBio (ANAB) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AnaptysBio (ANAB) has outperformed uniQure N.V. (QURE) over the past year, gaining 76.6% versus a loss of 30.4%. Over five years, ANAB leads with a +124.8% price change compared with -32.9% for QURE. AnaptysBio is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.
AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | QURE |
|---|---|---|
| Share price | $46.63 | $19.35 |
| Market cap | $1.39B | $1.36B |
| 1-day change | -1.62% | -4.35% |
| YTD return | +44.28% | -19.14% |
| 1-year return | +76.58% | -30.42% |
| 5-year return | +124.76% | -32.86% |
| P/E ratio (TTM) | 7.15 | — |
| Forward P/E | 8.66 | — |
| EPS (TTM) | $6.52 | $-3.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $234.60M | $16.10M |
| Revenue growth (YoY) | +157.01% | -40.64% |
| Net income (latest FY) | $-13.23M | $-198.97M |
| Gross margin | — | 89.53% |
| Operating margin | 96.72% | -1151.38% |
| Net margin | -5.64% | -1236.00% |
| 52-week high | $72.36 | $51.72 |
| 52-week low | $26.01 | $8.73 |
| Distance from 52-week high | -35.56% | -62.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +87.11% | +207.03% |
| Average volume | 496.92K | 2.26M |
| Shares outstanding | 29.73M | 70.14M |
| Employees | — | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed QURE by 107.0 percentage points over the past year.
- AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs -40.64%).
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
ANAB vs QURE FAQ
Which is bigger, AnaptysBio or uniQure N.V.?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.39B compared with $1.36B for uniQure N.V. (QURE).
Which stock has performed better over the past year, ANAB or QURE?
ANAB returned +76.58% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.